Cosmetics & Personal Care
INOLEX GRANTED NEW PATENT FOR PRESERVATION TECHNOLOGY 1st February 2021
INOLEX is pleased to announce its recently issued patent that claims multifunctional preservation systems comprising caprylhydroxamic acid (CHA) and select diols for cosmetics, personal care, and pharmaceuticals. The patent claims the use of these ingredient compositions in formulations as well as blends comprising the CHA-diol compositions.
Caprylhydroxamic acid is a 100% natural and readily biodegradable chelating agent derived from coconut-sourced caprylic acid. CHA is a biostatic ingredient that provides a strong hurdle to microbial growth across a wide pH range (pH 4-8). Robust broad spectrum protection against contamination by bacteria, yeast, and mold is achieved via combination of CHA with medium chain terminal diols, such as caprylyl glycol, glyceryl caprylate, or caprylyl glyceryl ether.
“We have been advancing the industry with innovative preservation approaches for over two decades,” said David Plimpton, CEO and President of INOLEX. “This latest patent demonstrates our leadership in this category. Our broad portfolio of CHA offerings exemplifies our drive to bring effective alternative preservation mainstream.”
The company offers its portfolio of CHA-diol broad spectrum systems under the Spectrastat™ brand, with particular emphasis on 100% natural systems, such as Spectrastat™ G2 Natural MB (INCI: Caprylhydroxamic Acid (and) Glyceryl Caprylate (and) Glycerin).
The patent granted recognizes INOLEX’s ongoing commitment to innovation in the field of safe, effective, and sustainable options for preservation of formulated products. In October 2020, the Cosmetic Ingredient Review (CIR) released its final report on the safety of caprylhydroxamic acid as used in cosmetics, in which the independent Expert Panel for Cosmetic Ingredient Safety concluded that CHA is safe as used in the present practices of the industry. This conclusion further validated the outstanding track record of safety associated with CHA.
According to Dr. Michael Fevola, Vice President of Research & Development at INOLEX,
“As a company we have established high safety and transparency standards for all of our technologies. We proactively contributed our entire archive of safety and toxicological data on CHA for the benefit of our customers and their consumers. INOLEX also commissioned additional clinical safety studies and a quantitative risk assessment as requested by the Expert Panel to validate CHA safety at all use levels reported by CIR.”
To date, the use of CHA has been reported in over 5,000 product SKUs around the world, as documented by the Mintel Global New Products Database.